Calderon M A, Demoly P, Casale T, Akdis C A, Bachert C, Bewick M, Bilò B M, Bohle B, Bonini S, Bush A, Caimmi D P, Canonica G W, Cardona V, Chiriac A M, Cox L, Custovic A, De Blay F, Devillier P, Didier A, Di Lorenzo G, Du Toit G, Durham S R, Eng P, Fiocchi A, Fox A T, van Wijk R Gerth, Gomez R M, Haathela T, Halken S, Hellings P W, Jacobsen L, Just J, Tanno L K, Kleine-Tebbe J, Klimek L, Knol E F, Kuna P, Larenas-Linnemann D E, Linneberg A, Matricardi M, Malling H J, Moesges R, Mullol J, Muraro A, Papadopoulos N, Passalacqua G, Pastorello E, Pfaar O, Price D, Del Rio P Rodriguez, Ruëff R, Samolinski B, Scadding G K, Senti G, Shamji M H, Sheikh A, Sisul J C, Sole D, Sturm G J, Tabar A, Van Ree R, Ventura M T, Vidal C, Varga E M, Worm M, Zuberbier T, Bousquet J
National Heart and Lung Institute, Royal Brompton Hospital NHS, Imperial College London, London, UK.
Unité d'allergologie, Département de Pneumologie et AddictologieHôpital Arnaud de Villeneuve, CHRU de Montpellier, Sorbonne Universités, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, 75013 Paris, France.
Clin Transl Allergy. 2016 Nov 23;6:41. doi: 10.1186/s13601-016-0131-x. eCollection 2016.
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
过敏性疾病通常在生命早期出现并持续终生。在变应原免疫治疗中应考虑这种生命历程观点。特别是，了解这种治疗方法是否可用于老年人至关重要。本文由气道疾病综合护理途径工作组、欧洲积极和健康老龄化创新伙伴关系（数字经济和社会司与卫生司）的慢性呼吸道疾病模型编写。它考虑了（1）政治背景，（2）生命周期内变应原免疫治疗的基本原理，（3）治疗的未满足需求，特别是在学龄前儿童和老年人中，（4）战略框架以及协同变应原免疫治疗当前举措、其机制和积极和健康老龄化概念的实际方法。
